Suven Life Sciences has been selected as one of the “Best Under A Billion” companies by Forbes Asia 2014.
Forbes Asia’s “Best Under A Billion” list highlights 200 of the best small and mid-sized listed companies in Asia Pacific with annual revenue under $1 billion. To qualify for the selection, companies must have revenue between $5 million and $1 billion, positive net income and be publicly traded for at least a year. From a universe of 17,000 companies, qualified candidates are screened on sales growth, earnings growth and return on equity. The result is a final list featuring 200 exceptional small and mid-sized companies from Asia Pacific.
In recognition of the achievement of these 200 “Best Under A Billion” Companies, Forbes Asia is organising an Award Ceremony and Dinner and Suven will receive the award on 9th December 2014 in Bangkok, Thailand.
The company has 12 internally-discovered therapeutic drug candidates currently in per-clinical stage of development targeting conditions such as ADHD, dementia, major depressive disorder (MDD), huntington’s disease, parkinson’s disease and obesity in addition to developmental candidate SUVN-502 for alzheimer’s disease and schizophrenia.
EP News Bureau– Mumbai